Suspected Drug-Induced Rhabdomyolysis From the Combination of Atorvastatin,Amiodarone,and Ciprofloxacin

Abstract

Get full access to this article

View all access options for this article.

References

Bellosta

Paoletti

Corsini

Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation. 2004;109(23, suppl 1):III50-III57. doi:10.1161/01.CIR.0000131519.15067.1f

Lipitor®. Package insert. Pfizer; 2020.

Ricaurte

Guirguis

Taylor

Zabriskie

Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possibly hepatotoxicity. Ann Pharmacother. 2006;40:753-757. doi:10.1345/aph.1G462

Roten

Schoenenberger

Krähenbül

Schlienger

RG.

Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother. 2004;38:978-981. doi:10.1345/aph.1D498

Goldier

Brogan

Boyle

JG.

Ciprofloxacin and statin interaction: a cautionary tale of rhabdomyolysis. BMJ Case Rep. 2016;2016:bcr2016216048. doi:10.1136/bcr-2016-216048

Naranjo

Busto

Sellers

, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245. doi:10.1038/clpt.1981.154

Horn

Hansten

Chan

LN.

Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007;41: 674-680. doi:10.1345/aph.1H423